Show simple item record

dc.contributor.authorBarnes, Edward L
dc.contributor.authorDeepak, Parakkal
dc.contributor.authorBeniwal-Patel, Poonam
dc.contributor.authorRaffals, Laura
dc.contributor.authorKayal, Maia
dc.contributor.authorDubinsky, Marla
dc.contributor.authorChang, Shannon
dc.contributor.authorHiggins, Peter D R
dc.contributor.authorBarr, Jennifer I
dc.contributor.authorGalanko, Joseph
dc.contributor.authorJiang, Yue
dc.contributor.authorCross, Raymond K
dc.contributor.authorLong, Millie D
dc.contributor.authorHerfarth, Hans H
dc.date.accessioned2022-09-13T12:34:15Z
dc.date.available2022-09-13T12:34:15Z
dc.date.issued2022-08-02
dc.identifier.urihttp://hdl.handle.net/10713/19722
dc.description.abstractBackground. Much of our understanding about the natural history of pouch-related disorders has been generated from selected populations. We designed a geographically diverse, prospective registry to study the disease course among patients with 1 of 4 inflammatory conditions of the pouch. The primary objectives in this study were to demonstrate the feasibility of a prospective pouch registry and to evaluate the predominant treatment patterns for pouch-related disorders. Methods. We used standardized diagnostic criteria to prospectively enroll patients with acute pouchitis, chronic antibiotic-dependent pouchitis (CADP), chronic antibiotic refractory pouchitis (CARP), or Crohn’s disease (CD) of the pouch. We obtained detailed clinical and demographic data at the time of enrollment, along with patient-reported outcome (PRO) measures. Results. We enrolled 318 patients (10% acute pouchitis, 27% CADP, 12% CARP, and 51% CD of the pouch). Among all patients, 55% were on a biologic or small molecule therapy. Patients with CD of the pouch were more likely to use several classes of therapy (P < .001). Among patients with active disease at the time of enrollment, 23% with CARP and 40% with CD of the pouch were in clinical remission at 6 months after enrollment. Conclusions. In a population where most patients had refractory inflammatory conditions of the pouch, we established a framework to evaluate PROs and clinical effectiveness. This infrastructure will be valuable for long-term studies of real-world effectiveness for pouch-related disorders.en_US
dc.description.urihttps://doi.org/10.1093/crocol/otac030en_US
dc.language.isoenen_US
dc.publisherCrohn’s & Colitis Foundationen_US
dc.relation.ispartofCrohn's & Colitis 360en_US
dc.rights© The Author(s) 2022. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.en_US
dc.subjectCrohn’s disease of the pouchen_US
dc.subjectileal pouch-anal anastomosisen_US
dc.subjectpouchitisen_US
dc.subjectreal-world effectivenessen_US
dc.titleTreatment Patterns and Standardized Outcome Assessments Among Patients With Inflammatory Conditions of the Pouch in a Prospective Multicenter Registry.en_US
dc.typeArticleen_US
dc.identifier.doi10.1093/crocol/otac030
dc.identifier.pmid36082341
dc.source.journaltitleCrohn's & colitis 360
dc.source.volume4
dc.source.issue3
dc.source.beginpageotac030
dc.source.endpage
dc.source.countryEngland


This item appears in the following Collection(s)

Show simple item record